×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SPRY – ars pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SPRY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
07:20 am
spry
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Low
Report
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
11/14
09:08 am
spry
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]
Medium
Report
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]
11/14
02:21 am
spry
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]
Medium
Report
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]
11/13
06:30 am
spry
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/11
07:45 am
spry
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]
11/11
07:00 am
spry
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Low
Report
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
11/9
05:36 pm
spry
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]
Low
Report
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]
11/6
08:00 am
spry
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
Low
Report
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:30 pm
spry
Form 4 ARS Pharmaceuticals, For: Nov 19 Filed by: Tanimoto Sarina
Medium
Report
Form 4 ARS Pharmaceuticals, For: Nov 19 Filed by: Tanimoto Sarina
11/21
04:30 pm
spry
Form 4 ARS Pharmaceuticals, For: Nov 19 Filed by: Lowenthal Richard E
Medium
Report
Form 4 ARS Pharmaceuticals, For: Nov 19 Filed by: Lowenthal Richard E
11/15
03:21 pm
spry
Form 144 ARS Pharmaceuticals, Filed by: Chakma Justin
Low
Report
Form 144 ARS Pharmaceuticals, Filed by: Chakma Justin
11/14
04:30 pm
spry
Form 4 ARS Pharmaceuticals, For: Nov 12 Filed by: Tanimoto Sarina
Low
Report
Form 4 ARS Pharmaceuticals, For: Nov 12 Filed by: Tanimoto Sarina
11/14
04:30 pm
spry
Form 4 ARS Pharmaceuticals, For: Nov 12 Filed by: Lowenthal Richard E
Low
Report
Form 4 ARS Pharmaceuticals, For: Nov 12 Filed by: Lowenthal Richard E
11/13
08:17 pm
spry
Form 4 ARS Pharmaceuticals, For: Nov 11 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Medium
Report
Form 4 ARS Pharmaceuticals, For: Nov 11 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
11/13
07:03 am
spry
Form 10-Q ARS Pharmaceuticals, For: Sep 30
High
Report
Form 10-Q ARS Pharmaceuticals, For: Sep 30
11/13
07:01 am
spry
Form 8-K ARS Pharmaceuticals, For: Nov 13
High
Report
Form 8-K ARS Pharmaceuticals, For: Nov 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: